肝细胞癌免疫治疗的研究进展

摘要

近年来，肝细胞癌（HCC）的免疫治疗取得显著进展，其与靶向治疗、介入治疗、放射治疗、肿瘤消融治疗等联合应用为HCC患者带来新的希望。本文对HCC免疫治疗策略的应用现状、联合治疗的前景以及未来发展的方向等最新研究进展进行综述，并分析当前HCC免疫治疗的关键问题和潜在的解决途径，为进一步研究方向和临床实践提供参考。

关键词

肝细胞癌 / 免疫治疗 / 免疫微环境 / 免疫检查点抑制剂

参考文献

[1] 袁振刚， 叶胜龙 . 肝细胞癌系统治疗策略：现状和前景[J/OL]. 中华肝脏病杂志， 2024， 32（6）： 565-571. DOI: 10.3760/cma.j.cn501113—20240412—00200.

[2] Vogel A , Meyer T , Sapisochin G , et al. Hepatocellular carcinoma[J/OL]. Lancet, 2022, 400(10360): 1345-1362. DOI: 10.1016/S0140—6736(22)01200—4.

[3] Llovet J M , Ricci S , Mazzaferro V , et al. Sorafenib in advanced hepatocellular carcinoma[J/OL]. NEJM, 2008, 359(4): 378-390. DOI: 10.1056/NEJMoa0708857.

[4] 徐家豪， 尹东旭， 李宇辰， 等 . 晚期肝细胞癌的系统治疗[J]. 临床肝胆病杂志， 2024， 40（11）： 2306-2314.

[5] 国际肝胆胰协会中国分会肝胆胰MDT专业委员会， 中华医学会外科学分会肝脏外科学组， 中国老年医学学会普外科分会《中华消化外科杂志》编辑委员会 . 肝细胞癌围手术期免疫治疗多学科协作专家共识（2025版）[J]. 中华消化外科杂志， 2025， 24（6）： 678-689. DOI: 10.3760/cma.j.cn115610—20250609—00278.

[6] 中华人民共和国国家卫生健康委员会医政司 . 原发性肝癌诊疗指南（2024年版）[J]. 中华消化外科杂志， 2024， 23（4）： 429-478. DOI: 10.3760/cma.j.cn15610—20240415—00203.

[7] Cassioli C , Baldari CT . The Expanding Arsenal of Cytotoxic T Cells[J/OL]. Front Immunol, 2022, 13: 883010. DOI: 10.3389/fimmu.2022.883010.

[8] Llovet J M , Castet F , Heikenwalder M , et al. Immunotherapies for hepatocellular carcinoma[J/OL]. Nat Rev Clin Oncol, 2022, 19(3): 151-172. DOI: 10.1038/s41571—021—00573—2.

[9] Mellman I , Chen D S , Powles T , et al. The cancer—immunity cycle: Indication, genotype, and immunotype[J/OL]. Immunity, 2023, 56(10): 2188-2205. DOI: 10.1016/j.immuni.2023.09.011.

[10] Li X , Ramadori P , Pfister D , et al. The immunological and metabolic landscape in primary and metastatic liver cancer[J/OL]. Nat Rev Cancer, 2021, 21(9): 541-557. DOI: 10.1038/s41568—021—00383—9.

[11] Oura K , Morishita A , Tani J , et al. Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review[J/OL]. Int J Mol Sci, 2021, 22(11): 5801. DOI: 10.3390/ijms22115801.

[12] Xia L , Oyang L , Lin J , et al. The cancer metabolic reprogramming and immune response[J/OL]. Mol Cancer, 2021, 20(1): 28. DOI: 10.1186/s12943—021—01316—8.

[13] Giles J R , Globig A M , Kaech S M , et al. CD8 ⁺ T cells in the cancer—immunity cycle [J/OL]. Immunity, 2023, 56(10): 2231-2253. DOI: 10.1016/j.immuni.2023.09.005.

[14] Dai E , Zhu Z , Wahed S , et al. Epigenetic modulation of antitumor immunity for improved cancer immunotherapy[J/OL]. Mol Cancer, 2021, 20(1): 171. DOI: 10.1186/s12943—021—01464—x.

[15] Platten M , Nollen E A A , Röhrig U F , et al. Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond[J/OL]. Nat Rev Drug Discov, 2019, 18(5): 379-401. DOI: 10.1038/s41573—019—0016—5.

[16] El—Khoueiry AB , Sangro B , Yau T , et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open—label, non—comparative, phase 1/2 dose escalation and expansion trial[J/OL]. Lancet, 2017, 389(10088): 2492-2502. DOI: 10.1016/S0140—6736(17)31046—2.

[17] Zhu A X , Finn R S , Edeline J , et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE—224): a non—randomised, open—label phase 2 trial[J/OL]. Lancet Oncol, 2018, 19(7): 940-952. DOI: 10.1016/S1470—2045(18)30351—6.

[18] Qin S , Ren Z , Meng Z , et al. Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open—label, parallel—group, randomised, phase 2 trial[J/OL]. Lancet Oncol, 2020, 21(4): 571-580. DOI: 10.1016/S1470—2045(20)30011—5.

[19] Yau T , Park J W , Finn R S , et al. Nivolumab versus sorafenib in advanced hepatocellular carcinoma(CheckMate 459): a randomised, multicentre, open—label, phase 3 trial[J/OL]. Lancet Oncol, 2022, 23(1): 77-90. DOI: 10.1016/S1470—2045(21)00604—5.

[20] Finn R S , Ryoo B Y , Merle P , et al. Pembrolizumab As Second—Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE—240: A Randomized, Double—Blind, Phase III Trial[J/OL]. J Clin Oncol, 2020, 38(3): 193-202. DOI: 10.1200/JCO.19.01307.

[21] Qin S , Kudo M , Meyer T , et al. Tislelizumab vs Sorafenib as First—Line Treatment for Unresectable Hepatocellular Carcinoma: A Phase 3 Randomized Clinical Trial[J/OL]. JAMA Oncol, 2023, 9(12): 1651. DOI: 10.1001/jamaoncol.2023.4003.

[22] Cheng A L , Qin S , Ikeda M , et al. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma[J/OL]. J Hepatol, 2022, 76(4): 862-873. DOI: 10.1016/j.jhep.2021.11.030.

[23] Ren Z , Xu J , Bai Y , et al. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT—32): a randomised, open—label, phase 2—3 study[J/OL]. Lancet Oncol, 2021, 22(7): 977-990. DOI: 10.1016/S1470—2045(21)00252—7.

[24] Qin S , Chan SL , Gu S , et al. Camrelizumab plus rivoceranib versus sorafenib as first—line therapy for unresectable hepatocellular carcinoma (CARES—310): a randomised, open—label, international phase 3 study[J/OL]. Lancet, 2023, 402(10408): 1133-1146. DOI: 10.1016/S0140—6736(23)00961—3.

[25] Llovet J M , Kudo M , MERLE P , et al. Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma(LEAP—002): a randomised, double—blind, phase 3 trial[J/OL]. Lancet Oncol, 2023, 24(12): 1399-1410. DOI: 10.1016/S1470—2045(23)00469—2.

[26] Kelley RK , Rimassa L , Cheng AL , et al. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC—312): a multicentre, open—label, randomised, phase 3 trial[J/OL]. Lancet Oncol, 2022, 23(8): 995-1008. DOI: 10.1016/S1470—2045(22)00326—6.

[27] Sangro B , Chan S L , Kelley R K , et al. Four—year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma[J/OL]. Ann Oncol, 2024, 35(5): 448-457. DOI: 10.1016/j.annonc.2024.02.005.

[28] Abou—alfa G K , Lau G , Kudo M , et al. Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma[J/OL]. NEJM Evid, 2022, 1(8): EVIDoa2100070. DOI: 10.1056/EVIDoa2100070.

[29] Galle P R , Decaens T , Kudo M , et al. Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first—line treatment for unresectable hepatocellular carcinoma (uHCC): First results from CheckMate 9DW[J/OL]. J Clin Oncol, 2024, 42(17_suppl): LBA4008— LBA4008. DOI: 10.1200/JCO.2024.42.17_suppl.LBA4008.

[30] Zhong B Y , Fan W , Guan J J , et al. Combination locoregional and systemic therapies in hepatocellular carcinoma[J/OL]. Lancet Gastroenterol Hepatol, 2025, 10(4): 369-386. DOI: 10.1016/S2468—1253(24)00247—4.

[31] Vogel A , Saborowski A , Hinrichs J , et al. LBA37 IMMUTACE: A biomarker—orientated, multi center phase II AIO study of transarterial chemoembolization (TACE) in combination with nivolumab performed for intermediate stage hepatocellular carcinoma (HCC)[J/OL]. Ann Oncol, 2021, 32(4): S1312. DOI: 10.1016/j.annonc.2021.08.2114.

[32] Zhang TQ , Geng ZJ , Zuo MX , et al. Camrelizumab (a PD—1 inhibitor) plus apatinib (an VEGFR—2 inhibitor) and hepatic artery infusion chemotherapy for hepatocellular carcinoma in Barcelona Clinic Liver Cancer stage C (TRIPLET): a phase II study[J/OL]. Sig Transduct Target Ther, 2023, 8(1): 413. DOI: 10.1038/s41392—023—01663—6.

[33] O’Kane GM , Mesci AM , Chen EX , et al. Pembrolizumab and stereotactic radiotherapy combined in subjects with advanced HCC: A phase II study(PEMRAD)[J/OL]. JCO, 2025, 43(4_suppl): 602— 602. DOI: 10.1200/JCO.2025.43.4_suppl.602.

[34] Kudo M , Ueshima K , Nakahira S , et al. Final results of adjuvant nivolumab for hepatocellular carcinoma (HCC) after surgical resection (SR) or radiofrequency ablation (RFA) (NIVOLVE): A phase 2 prospective multicenter single—arm trial and exploratory biomarker analysis[J/OL]. JCO, 2022, 40(4_suppl): 416— 416. DOI: 10.1200/JCO.2022.40.4_suppl.416.

[35] Kudo M , Guo Y , Hua Y , et al. TALENTACE: A phase III, open—label, randomized study of on—demand transarterial chemoembolization combined with atezolizumab + bevacizumab or on—demand transarterial chemoembolization alone in patients with untreated hepatocellular carcinoma[J/OL]. JCO, 2022, 40(4_suppl): TPS487— TPS487. DOI: 10.1200/JCO.2022.40.4_suppl.TPS487.

[36] Sangro B , Kudo M , Erinjeri J P , et al. Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD—1): a multiregional, randomised, double—blind, placebo—controlled, phase 3 study[J/OL]. Lancet, 2025, 405(10474): 216-232. DOI: 10.1016/S0140—6736(24)02551—0.

[37] Kudo M , Ren Z , Guo Y , et al. Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non—metastatic hepatocellular carcinoma (LEAP—012): a multicentre, randomised, double—blind, phase 3 study[J/OL]. Lancet, 2025, 405(10474): 203-215. DOI: 10.1016/S0140—6736(24)02575—3.

[38] Finn R S , Ryoo B Y , Hsu C H , et al. Tiragolumab in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (MORPHEUS—Liver): a randomised, open—label, phase 1b—2, study[J/OL]. Lancet Oncol, 2025, 26(2): 214-226. DOI: 10.1016/S1470—2045(24)00679—X.

[39] Li D , Rau K M , Yu M L , et al. Results from a phase 2 study of triplet blockade of the IL—27, PD—(L)1, and VEGF pathways with casdozokitug (casdozo, CHS—388) in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (uHCC)[J/OL]. J Clin Oncol, 2025, 43(4_suppl): 605— 605. DOI: 10.1200/JCO.2025.43.4_suppl.605.

[40] Asciolla JJ , Wu X , Adamopoulos C , et al. Resistance mechanisms and therapeutic strategies of CDK4 and CDK6 kinase targeting in cancer[J/OL]. Nat Cancer, 2025, 6(1): 24-40. DOI: 10.1038/s43018—024—00893—z.

[41] Zhang N , Yang X , Piao M , et al. Biomarkers and prognostic factors of PD—1/PD—L1 inhibitor—based therapy in patients with advanced hepatocellular carcinoma[J/OL]. Biomark Res, 2024, 12(1): 26. DOI: 10.1186/s40364—023—00535—z.

[42] Chow P , Chen M , Cheng A L , et al. Abstract CT003: IMbrave050: Phase 3 study of adjuvant atezolizumab + bevacizumab versus active surveillance in patients with hepatocellular carcinoma(HCC) at high risk of disease recurrence following resection or ablation[J/OL]. Cancer Res, 2023, 83(8_Supplement): CT003— CT003. DOI: 10.1158/1538—7445.AM2023—CT003.

[43] Postow M A , Sidlow R , Hellmann M D . Immune—Related Adverse Events Associated with Immune Checkpoint Blockade[J/OL]. NEJM, 2018, 378(2): 158-168. DOI: 10.1056/NEJMra1703481.

[44] Sangro B , Sarobe P , Hervás—stubbs S , et al. Advances in immunotherapy for hepatocellular carcinoma[J/OL]. Nat Rev Gastro Hepat, 2021, 18(8): 525-543. DOI: 10.1038/s41575—021—00438—0.

[45] Shen J , Li Z , Liu X , et al. Sensing of Liver—Derived Nicotinamide by Intestinal Group 2 Innate Lymphoid Cells Links Liver Cirrhosis and Ulcerative Colitis Susceptibility[J/OL]. Adv Sci, 2024, 11(38): e2404274. DOI: 10.1002/advs.202404274.

[46] Plachouri K M , Vryzaki E , Georgiou S . Cutaneous Adverse Events of Immune Checkpoint Inhibitors: A Summarized Overview[J/OL]. Curr Drug Saf, 2019, 14(1): 14-20. DOI: 10.2174/1574886313666180730114309.

[47] Yau T , Kang Y K , Kim T Y , et al. Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial[J/OL]. JAMA Oncol, 2020, 6(11): e204564. DOI: 10.1001/jamaoncol.2020.4564.

[48] Verset G , Borbath I , Karwal M , et al. Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open—Label, Phase II KEYNOTE—224 Trial[J/OL]. Clin Cancer Res, 2022, 28(12): 2547-2554. DOI: 10.1158/1078—0432.CCR—21—3807.

[49] Finn R S , Ikeda M , Zhu A X , et al. Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma[J/OL]. J Clin Oncol, 2020, 38(26): 2960-2970. DOI: 10.1200/JCO.20.00808.

[50] Finn R S , Qin S , Ikeda M , et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma[J/OL]. NEJM, 2020, 382(20): 1894-1905. DOI: 10.1056/NEJMoa1915745.

[51] Lei Q , Wang D , Sun K , et al. Resistance Mechanisms of Anti—PD1/PDL1 Therapy in Solid Tumors[J/OL]. Front Cell Dev Biol, 2020, 8: 672. DOI: 10.3389/fcell.2020.00672.

[52] Joller N , Kuchroo V K . Tim—3, Lag—3, and TIGIT[J/OL]. Currt Top Microbiol, 2017, 410: 127-156. DOI: 10.1007/82_2017_62.

[53] Maini M K , Pallett L J . Defective T—cell immunity in hepatitis B virus infection: why therapeutic vaccination needs a helping hand[J/OL]. Lancet Gastroenterol Hepatol, 2018, 3(3): 192-202. DOI: 10.1016/S2468—1253(18)30007—4.